Frontlight ResearchEarly access
CompletedPhase 1
Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain
Key facts
- Who runs it
- Contineum Therapeutics
- Where
- Duncansville, Hartsdale, Marietta, Phoenix, and Salt Lake City, United StatesSee the 5 sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 43 people enrolled
- Started
- 4 Feb 2025
- Ended
- 20 Jan 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- PIPE-791
- Placebo
- Record updated
- 18 March 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Male or female 18 to 70 years of age, inclusive, at the first Screening visit
- Only one of the following chronic pain diagnoses at least 6 months prior to Screening:
- Osteoarthritis of the knee OR low back pain (with or without painful lumbosacral radiculopathy)
- Plain radiographs of the knee or lumbar spine consistent with diagnosis within 9 months prior to or during Screening
- History of related daily pain for at least 6 months prior to Screening
- Have a body mass index <40 (inclusive) at Screening
- Willing to maintain a consistent regimen of any ongoing (stable format and frequency for the duration of study participation) non-pharmacologic pain-relieving therapies
- Willing to discontinue medications taken for chronic pain conditions and usage of transcutaneous electrical nerve stimulation for the duration of the study
- Male or female subjects with reproductive potential agree to comply with a highly effective contraceptive method as per protocol through 90 days after last study drug administration
- Subjects taking systemic hormone-replacement therapy must be on a stable dose and regimen for at least 1 month prior to Screening
- General good medical health with no clinically significant or relevant abnormalities except those attributed to the underlying chronic pain condition, including medical history, physical exam, vital signs, ECG, and laboratory evaluations (hematology, chemistry, and urinalysis) as assessed by the Investigator
- Ability to use an eDiary to record daily pain scores
Who cannot take part
- Concurrent diagnosis of fibromyalgia or evidence of chronic widespread pain, or other pain that may interfere with the assessment of CLBP or COAP
- Received capsaicin treatment (e.g., Qutenza) within the past 3 months prior to screening
- History of prior lumbar or thoracic spine surgery (e.g., discectomies, laminectomies, foraminotomies, or fusion)
- History of refractory chronic pain after multiple failed treatments as determined by the Investigator (e.g., no response to all of the following: surgery and/or nerve blocks, a regimen of at least two non-opioid pharmacotherapies, and physical rehabilitation, and weak opioids)
- Have surgery planned during the study for any reason, related or not, to the disease state under evaluation
- History of Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease, sarcoidosis, or amyloidosis
- Diagnosed with OA during childhood or adolescence, including post-traumatic OA or OA due to genetic (e.g., hip dysplasia) or congenital (e.g., metabolic disorders) conditions
- History of or clinical signs or symptoms of active joint infection, crystal disease of the knee, or a history of arthritis due to crystals (e.g., gout, pseudo gout)
- Demonstrated noncompliance recording daily Numerical Rating Scale (NRS) scores during Screening
- Have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest, e.g., an ablation procedure
- Are non-ambulatory (use of assistive devices is allowed)
Where in United States
- Altoona Center of Clinical ResearchDuncansville, United States
- Drug Trials AmericaHartsdale, United States
- Drug Studies AmericaMarietta, United States
- Arizona Research CenterPhoenix, United States
- JBR Clinical ResearchSalt Lake City, United States
About the trial
What the trial wants to find out
The primary goal of this clinical trial is to learn if PIPE-791 is safe and well-tolerated in adults with chronic osteoarthritis pain (COAP) or chronic low back pain (CLBP). The study will also explore whether PIPE-791 lowers pain in people with COAP or CLBP.
Read full original descriptionShow less
Subjects will:
* Complete a washout period to stop their current pain medications. * Take a daily dose of PIPE-791 or placebo for 4 weeks, then reverse treatment assignment for another 4 weeks. * Record pain levels and track dosing in a daily e-diary. * Visit the clinic for checkups and lab tests throughout the study. * Complete phone assessments during the treatment periods.
The 2 groups in the trial
- Active followed by PlaceboTreatment being tested
Treatment: PIPE-791 and Placebo
- Placebo followed by ActiveTreatment being tested
Treatment: PIPE-791 and Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Crossover Multicenter Study to Explore the Safety and Efficacy of Oral PIPE-791 as Treatment in Subjects With Chronic Osteoarthritis Pain (COAP) or Chronic Low Back Pain (CLBP)
- Publications
- Record updated
- 18 March 2026